Two 59%+ winners, four above 25% in Aug – How this AI model keeps picking winners
Solomon Moshkevich, President, Clinical Diagnostics at Natera, Inc. (NASDAQ:NTRA), sold a total of 875 shares of common stock on August 14, 2025. The shares were sold at prices ranging from $155.4248 to $155.46, for a total value of approximately $136,027. The stock currently trades at $163.02, having delivered a strong 31.49% return over the past year. According to InvestingPro analysis, Natera’s stock appears overvalued at current levels.
The sales were executed to cover tax obligations related to the vesting of restricted stock units (RSUs). On August 12, Moshkevich acquired 1,675 shares of Natera common stock upon the vesting of RSUs. These RSUs, granted on October 22, 2021, vest upon achieving certain milestones related to time and business performance. The company has shown impressive revenue growth of 44.38% and maintains a strong financial health score of "GREAT" according to InvestingPro’s comprehensive analysis.
Following these transactions, Moshkevich directly owns 123,859 shares of Natera, representing a stake in the $22.46 billion market cap company. With a healthy current ratio of 3.72, Natera maintains strong liquidity to meet its short-term obligations.
In other recent news, Natera reported its second-quarter 2025 earnings, showcasing a significant revenue beat with $546.6 million, surpassing expectations by 14.85%. However, the company’s earnings per share (EPS) came in at -$0.74, missing the forecasted -$0.62. Despite the EPS miss, the market responded positively to the strong revenue performance. RBC Capital raised its price target for Natera to $255 from $251, citing "another noteworthy quarter" for the company. Similarly, Bernstein SocGen Group increased its price target to $205 from $200, highlighting the company’s strong revenue performance. TD Cowen also adjusted its price target to $215 from $200, maintaining a Buy rating and acknowledging the strong quarterly performance. These recent developments reflect a positive outlook from analysts on Natera’s financial health and growth potential.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.